This is a Phase 1b/2, multicenter, open-label, basket study evaluating ACR-368, an adenosine triphosphate-competitive selective inhibitor of checkpoint kinase (CHK)1 and CHK2, as monotherapy and in combination with ultralow-dose gemcitabine (ULDG), in the treatment of subjects with histologically confirmed, locally advanced or metastatic, recurrent platinum-resistant high-grade ovarian or endometrial adenocarcinoma, or platinum-resistant urothelial carcinoma (hereafter referred to as ovarian, endometrial, and urothelial, respectively).

Have you been diagnosed with a locally advanced or metastatic solid tumor cancer? Are there no available curative treatment options, or has your prior standard of care treatment failed? You may be able to take part in this gene therapy research study to learn more about using your own modified immune cells as a possible treatment.

If you have Testosterone-driven Salivary Gland Cancer, you may be able to participate in a research study testing the anti-cancer drug Darolutamide.

Have you been diagnosed with Prostate, Bladder, or Kidney Cancer? If so, you may be able to take part in a research study investigating the optimal way to combine or sequence therapies in patients with Rare Genitourinary Tumors.

The purpose of this study is to test good and bad effects of different drugs against metastatic brain tumors with altered genes. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in brain metastases and have found several genes that are altered, or mutated. There are medications that target these genes. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your metastatic cancer. The usual approach is defined as care most people get for your metastatic cancer.

We are trying to understand responses to food labels among adults who identify as Hispanic/Latino.

Have you been diagnosed with extremity soft tissue sarcoma and are scheduled to have standard of care radiotherapy (XRT) followed by surgery to treat your cancer? XRT is effective in managing extremity soft tissue sarcoma, however, it is associated with risks, such as damage to healthy tissue, and complications in post-surgery wound healing. **This is a hybrid decentralized study where some if not all assessments may be performed close to your home.**

Did you know that over 250 million persons are affected by Osteoarthritis? It is the leading cause of disability among adults and has no cure. Prevention of OA is preferable to treatment and females are affected at nearly twice the rate as males. If you are a female, at least 50 years of age, overweight, with no or occasional knee pain, you may be able to participate in a research study to find out if a diet and exercise program or a health education program prevent knee OA.

Did you have head or neck cancer? Have you completed radiation in the past 3 years or more and now have dry mouth? You may be able to take part in a research study to help us learn if a gene therapy can help people with dry mouth due to radiation therapy.

Have you been diagnosed with high-risk early triple-negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene? If you still have evidence of TNBC in your breast or lymph node tissue after receiving treatment and surgery, you may qualify for this clinical research study. This study will test an experimental drug combination to find out which treatment is better at delaying the return of cancer.